What is Rad AI?
Headquartered in San Francisco, Rad AI is fundamentally transforming the practice of radiology through a suite of intelligent tools designed by radiologists for clinicians. The company's platform streamlines complex workflows by automating repetitive manual tasks, thereby enhancing daily productivity and diagnostic accuracy. By integrating seamlessly into existing hospital systems, Rad AI provides high-quality radiology reports that empower ordering clinicians to make faster, more informed decisions. This focus on clinical utility has positioned the firm as a leader in the intersection of artificial intelligence and medical diagnostics, effectively bridging the gap between high-volume imaging demands and the need for precision patient care.
How much funding has Rad AI raised?
Rad AI has raised a total of $118.5M across 4 funding rounds:
Debt
$150K
Debt
$325K
Series B
$50M
Series C
$68M
Debt (2020): $150K with participation from PPP
Debt (2021): $325K led by PPP
Series B (2024): $50M supported by Khosla Ventures, World Innovation Lab, and Artis Ventures Management Iii
Series C (2025): $68M featuring Advocate Health Care, Memorial Hermann Health System, Corewell Health, and Transformation Capital
Key Investors in Rad AI
Advocate Health Care
Advocate Health Care is the largest health system in Illinois and a national leader in population health management and accountable care.
Corewell Health
Corewell Health is a major integrated health system in Michigan, delivering comprehensive care across a vast network of hospitals and outpatient facilities.
Artis Ventures Management Iii
Artis Ventures is a venture capital firm focused on Tech Bio and Health, specializing in data-driven life sciences and scalable medical technologies.
What's next for Rad AI?
With this latest round of financing, Rad AI is well-positioned to scale its operations and deepen its integration within major health systems. The strategic backing from prominent healthcare providers and growth equity firms suggests a clear trajectory toward broader market adoption and the potential for expanding its AI-driven product portfolio. As the company moves into its next phase of growth, the focus will likely shift toward enhancing the interoperability of its diagnostic solutions and scaling its impact across diverse clinical settings, ensuring that the benefits of automated reporting reach a wider patient population while maintaining the highest standards of medical accuracy.
See full Rad AI company page
